Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MELK | Q14680 | 14/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23346310 | 0.88 | LMNA (0.39) | CDK2MEN1KMT2AMAPK1MAPT | |
| SCHEMBL23922749 | 0.87 | SIGMAR1 (0.39) | SIGMAR1CDK2MELKMEN1KMT2A | |
| SCHEMBL30521130 | 0.86 | JAK1 (0.38) | CDK2MEN1KMT2AMAPK1PKM | |
| SCHEMBL28694729 | 0.86 | JAK1 (0.38) | CDK2MEN1KMT2AMAPK1PKM | |
| SCHEMBL28701153 | 0.85 | JAK2 (0.39) | CDK2MEN1KMT2AMAPK1MAPT | |
| SCHEMBL17967810 | 0.84 | JAK2 (0.41) | CDK2MELKKMT2AMAPT | |
| SCHEMBL30520832 | 0.83 | JAK1 (0.40) | CDK2 | |
| SCHEMBL28709513 | 0.83 | JAK1 (0.41) | CDK2MEN1KMT2AMAPK1MAPT | |
| SCHEMBL28709580 | 0.83 | JAK1 (0.40) | CDK2 | |
| SCHEMBL23179760 | 0.81 | CDK2 (0.37) | CDK2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660303-B2 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | KANCERA AB (SE) | 2023-05-30 | — | — | US | disclosed |
| EP-3481824-B1 | 2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2021-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660303-B2 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | ROR1, RORB, RORA | SIGMAR1 2236/4885CDK2 268/4885MELK 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.